Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 6 of 6

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

VRDN-001 vs teprotumumab inhibition of IGF-1 receptor signaling and ocular fibroblast cell growth

Rachel Newell; Tricia Nguyen; Vahe Bedian

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3041.

ARVO Annual Meeting Abstract June 2023

Design and Preclinical Characterization of VRDN-003, a Next-Generation, Half-life Extended Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED)

Rachel Newell; Yang Zhao; Vahe Bedian

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4044.

ARVO Annual Meeting Abstract June 2023

Preclinical Pharmacokinetics and Bioavailability of VRDN-002, a Next-Generation Half-Life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED)

Robert Henderson; Kelly Foster; Brent Dickinson; Vahe Bedian

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4039.

ARVO Annual Meeting Abstract June 2023

VRDN-002, a Next-Generation Half-life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Safety and Pharmacokinetic/Pharmacodynamic (PK/PD) Results in Healthy Volunteers

Kelly Foster; Angela She; Rochelle M. Summerfelt; Brent Dickinson; Barrett Katz; Pawel Wiczling; Vahe Bedian

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4038.

ARVO Annual Meeting Abstract June 2023

Preclinical Pharmacokinetics of VRDN-003, A Next-Generation Half-life Extended Antibody to the IGF-1 Receptor for Thyroid Eye Disease

Brent Dickinson; Kelly Foster; Vahe Bedian

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4043.

ARVO Annual Meeting Abstract June 2022

Characterization of VRDN-001, a High Affinity and Potent anti-Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitory Antibody for the Treatment of Thyroid Eye Disease (TED)

Vahe Bedian

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3994 – A0336.

Advertisement